[go: up one dir, main page]

BR9914648A - Processo para monitorar ação medicamentosa deinibidor de proteasoma - Google Patents

Processo para monitorar ação medicamentosa deinibidor de proteasoma

Info

Publication number
BR9914648A
BR9914648A BR9914648-7A BR9914648A BR9914648A BR 9914648 A BR9914648 A BR 9914648A BR 9914648 A BR9914648 A BR 9914648A BR 9914648 A BR9914648 A BR 9914648A
Authority
BR
Brazil
Prior art keywords
drug action
proteasome inhibitor
methods
monitor drug
proteasome
Prior art date
Application number
BR9914648-7A
Other languages
English (en)
Inventor
Gopalakrishina R Vaddi
Ross L Stein
Lawrence R Dick
Vito J Palombella
Peter J Elliott
Julian Adams
Teresa A Mccormack
Tephen J Brand
Dan R Burns
Eric S Lightcap
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of BR9914648A publication Critical patent/BR9914648A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"PROCESSO PARA MONITORAR AçãO MEDICAMENTOSA DEINIBIDOR DE PROTEASOMA". A invenção se refere aosprocessos para medir a atividade do proteasoma em amostrasbiológicas. Mais especificamente, a invenção se refere aosprocessos para monitorar a ação medicamentosa seguindoadministração in vivo de um inibidor de proteasoma. A invençãoprovê processos e equipamentos para monitorar a açãomedicamentosa farmacodinâmica e para determinar o regime dedose para um inibidor de proteasoma. A invenção também provêprocessos para determinar a atividade de linha de base doproteasoma em um mamífero.
BR9914648-7A 1998-10-20 1999-10-19 Processo para monitorar ação medicamentosa deinibidor de proteasoma BR9914648A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10491898P 1998-10-20 1998-10-20
US13138199P 1999-04-28 1999-04-28
PCT/US1999/024356 WO2000023614A1 (en) 1998-10-20 1999-10-19 Method for monitoring proteasome inhibitor drug action

Publications (1)

Publication Number Publication Date
BR9914648A true BR9914648A (pt) 2001-11-27

Family

ID=26802081

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914648-7A BR9914648A (pt) 1998-10-20 1999-10-19 Processo para monitorar ação medicamentosa deinibidor de proteasoma

Country Status (15)

Country Link
US (1) US6613541B1 (pt)
EP (1) EP1123412B1 (pt)
JP (1) JP4503182B2 (pt)
KR (1) KR20010080267A (pt)
CN (1) CN1331752A (pt)
AT (1) ATE278803T1 (pt)
AU (1) AU762373B2 (pt)
BR (1) BR9914648A (pt)
CA (1) CA2347275C (pt)
DE (1) DE69920940T2 (pt)
ES (1) ES2228118T3 (pt)
HK (1) HK1040533A1 (pt)
IL (2) IL142647A0 (pt)
NZ (1) NZ511197A (pt)
WO (1) WO2000023614A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10051716A1 (de) * 2000-10-12 2002-04-25 Ulrich Schubert Mittel zur Hemmung der Freisetzung, Reifung und Replikation von Retroviren
DK1326632T3 (da) 2000-10-12 2007-01-15 Viromics Gmbh Protease-inhibitorer til behandling af infektioner af hepatitisvirus
CA2429163C (en) 2000-11-16 2013-02-12 The Regents Of The University Of California Marine actinomycete taxon for drug fermentation and product discovery
JP4451663B2 (ja) * 2002-02-01 2010-04-14 プロメガ コーポレイション 生物発光プロテアーゼ分析方法
DE10316735A1 (de) 2002-04-05 2003-11-20 Viromics Gmbh Mittel zur Behandlung von Flaviviridae-Infektionen
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
DE10232902A1 (de) * 2002-07-19 2004-01-29 Bayer Cropscience Ag Verfahren zum Identifizieren von Inhibitoren des 20S und 26S Proteasoms
PL2441767T3 (pl) 2003-06-20 2015-11-30 Univ California Salinosporamidy i sposoby ich stosowania
CN102151261A (zh) * 2003-06-20 2011-08-17 尼瑞斯药品公司 [3.2.0]杂环化合物及其类似物在癌症、炎症和感染性疾病治疗中的应用
ES2315673T3 (es) * 2003-08-08 2009-04-01 F. Hoffmann-La Roche Ag Uso de la subunidad de 3 de proteina activadora de proteasoma (pse3) como marcador de cancer colorrectal.
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7553632B2 (en) * 2004-01-22 2009-06-30 Promega Corporation Luminogenic and nonluminogenic multiplex assay
US7416854B2 (en) 2004-01-22 2008-08-26 Promega Corporation Luminogenic and nonluminogenic multiplex assay
WO2005105827A2 (en) 2004-04-15 2005-11-10 Proteolix, Inc. Compounds for proteasome enzyme inhibition
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
EP2266988A1 (en) 2004-04-30 2010-12-29 Nereus Pharmaceuticals, Inc. [3.2.0] Heterocyclic compounds and methods of using the same
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
JP5108509B2 (ja) * 2004-05-10 2012-12-26 プロテオリックス， インコーポレイテッド 酵素阻害のための化合物
EP2100899A3 (en) * 2004-10-20 2009-09-30 Proteolix, Inc. Compounds for proteasome enzyme inhibition
MX2007006526A (es) 2004-12-03 2007-09-19 Dana Farber Cancer Inst Inc Composiciones y metodos para tratamiento de enfermedades neoplasicas.
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US20060193844A1 (en) * 2005-02-28 2006-08-31 Proteolix, Inc. Methods for enzyme inhibition
EP1929308A1 (en) * 2005-09-01 2008-06-11 Promega Corporation Cell-based luminogenic and nonluminogenic proteasome assays
MX2008006090A (es) * 2005-11-09 2008-10-23 Proteolix Inc Compuestos para inhibicion de la enzima.
AR057227A1 (es) * 2005-12-09 2007-11-21 Centocor Inc Metodo para usar antagonistas de il6 con inhibidores del proteasoma
RU2450016C2 (ru) 2006-06-19 2012-05-10 Протеоликс, Инк. Пептидные эпоксикетоны для ингибирования протеасомы
US20080118940A1 (en) * 2006-11-22 2008-05-22 Maher Albitar Proteasomal peptidase activity and the use thereof in clinical applications
US7824698B2 (en) 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
EP2142665B1 (en) 2007-04-13 2013-11-27 Promega Corporation Luminescent live and dead cell assay
KR20160086980A (ko) 2007-10-04 2016-07-20 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
US8394816B2 (en) 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
CA2723465A1 (en) 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Proteasome inhibitors
MX2011004225A (es) 2008-10-21 2011-06-21 Onyx Therapeutics Inc Terapia de combinacion con epoxicetonas peptidicas.
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
US20110053199A1 (en) * 2009-08-25 2011-03-03 Quest Diagnostics Investments Incorporated Ubiquitin proteasome system profiling and the use thereof in clinical applications for cancer diagnosis
US20110053198A1 (en) * 2009-08-25 2011-03-03 Quest Diagnostics Investments Incorporated Ubiquitin proteasome system profiling and the use thereof in clinical applications for proliferative hematological disorders
US20110053197A1 (en) * 2009-08-25 2011-03-03 Quest Diagnostics Investments Incorporated Ubiquitin proteasome system profiling and the use thereof in clinical applications for cancer diagnosis
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
CN102725300B (zh) 2009-12-22 2015-03-11 赛福伦公司 蛋白酶体抑制剂及其制备、纯化、和应用的方法
BR112012022060A2 (pt) 2010-03-01 2018-05-08 Onyx Therapeutics Inc composto para a inibição de imunoproteassoma
EP2555621A4 (en) 2010-04-07 2014-07-02 Onyx Therapeutics Inc CRYSTALLINE EPOXYCETONE PEPTIDE IMMUNOPROTEASOME INHIBITOR
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340736A (en) * 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
AU676721B2 (en) 1993-02-10 1997-03-20 Dana-Farber Cancer Institute Role of ATP-ubiquitin-dependent proteolysis in MHC-1 restricted antigen presentation and inhibitors thereof
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6335358B1 (en) * 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
CA2219867A1 (en) * 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
JP2002518020A (ja) * 1998-06-13 2002-06-25 ザーペックス バイオサイエンシズ リミティド プロテアソーム活性

Also Published As

Publication number Publication date
IL142647A0 (en) 2002-03-10
JP2002527114A (ja) 2002-08-27
EP1123412A1 (en) 2001-08-16
KR20010080267A (ko) 2001-08-22
WO2000023614A8 (en) 2000-07-13
DE69920940T2 (de) 2005-11-17
AU762373B2 (en) 2003-06-26
DE69920940D1 (de) 2004-11-11
CN1331752A (zh) 2002-01-16
CA2347275C (en) 2010-03-09
HK1040533A1 (zh) 2002-06-14
CA2347275A1 (en) 2000-04-27
JP4503182B2 (ja) 2010-07-14
IL142647A (en) 2006-04-10
US6613541B1 (en) 2003-09-02
ES2228118T3 (es) 2005-04-01
AU6433399A (en) 2000-05-08
EP1123412B1 (en) 2004-10-06
ATE278803T1 (de) 2004-10-15
WO2000023614A1 (en) 2000-04-27
NZ511197A (en) 2003-08-29

Similar Documents

Publication Publication Date Title
BR9914648A (pt) Processo para monitorar ação medicamentosa deinibidor de proteasoma
Lourbakos et al. Cleavage and activation of proteinase-activated receptor-2 on human neutrophils by gingipain-R from Porphyromonas gingivalis
BRPI0002963B1 (pt) processo e dispositivo medidor eletroquìmico para medir uma concentração de analito em uma amostra.
ES2192269T3 (es) Aparato para la deteccion magnetica altamente sensible de analitos.
PT1077634E (pt) Monitorizacao de substancias fisiologicas a analisar
IL141774A0 (en) Monitoring methods using particle delivery methods
ATE420204T1 (de) Verfahren zur detektion von erkrankungen
ATE246356T1 (de) Vorrichtung zum vorhersagen von physiologischen messwerten
DE60106228D1 (de) Elektrochemischer biosensor-teststreifen mit erkennungselektrode und auslesemessgerät, das diesen teststreifen verwendet
DE60042695D1 (de) Verfahren für den nachweis von erkrankungen
ES2132272T3 (es) Procedimiento para la determinacion de aductos de hemoglobina.
DE60011274D1 (de) Verfahren, reagenz und messkartusche zur bestimmung der gerinnungszeit
DE60043660D1 (de) Automatisches system und verfahren zur vor-ort-detektion von drogen
DE59914830D1 (de) Verfahren und testbesteck zur beurteilung der oxid messung ihrer antiradikalen aktivität
BR9006800A (pt) Dispositivo para manter produtos de sangue,processo para tratar uma amostra de produto de sangue e estojo de teste
Stork et al. Pharmacokinetics of extended relief vs regular release Tylenol in simulated human overdose
ATE437963T1 (de) In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blase
DE69221040D1 (de) Aktivätsmessungen des amylin
DK1185873T3 (da) Reportermolekyler og fremgangsmåde til analyse af höjspecifitetsproteaseraktivitet
BRPI0407750B8 (pt) método para detectar a presença de micoplasma em uma amostra de teste, uso de fosfato de acetila ou um seu precursor e/ou fosfato de carbamoíla ou um seu precursor, e, kit para uso na detecção de contaminação por micoplasma
AR078002A1 (es) Uso de catepsina h para identificar compuestos que modulan el dolor neuropatico
NO920624L (no) Reagens for paavisning av fibrinolytisk aktivitet
WO2004099784A3 (en) Method for determining a tissue degradation process by detection of fibromodulin neoepitopes
Bouman et al. The importance of anticoagulant agents in measuring platelet aggregation in patients treated with clopidogrel and aspirin
ATE408827T1 (de) Quantifizierung von stressbelastung

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.